Reuters - Mylan (MYL.O), the world’s No. 3 generic drugmaker, said on Wednesday that it had reshuffled its management after a report on its quality controls sparked volatility in its share price. Heather Bresch, formerly chief operating officer, is being promoted to the position of president, and Rajiv Malik will take on the role of chief operating officer, the company said. Most recently, Malik headed global technical operations, overseeing quality and regulatory affairs, among other areas.
